Key result
In a systematic review of 25 studies, evening administration of aspirin tended to achieve greater reductions in morning COX-1-dependent platelet reactivity compared to morning dosing.
Why the study?
Cardiovascular physiology shows circadian rhythms affecting platelet reactivity and events, but the impact of timing antiplatelet therapy on efficacy is unclear.
Does evening administration of antiplatelet therapy improve diurnal variability in platelet reactivity in adults compared to morning administration?
Systematic Review (n=25)
Does evening administration of antiplatelet therapy improve diurnal variability in platelet reactivity in adults compared to morning administration?
Evening aspirin administration may enhance chronopharmacological efficacy by reducing morning platelet reactivity, but robust randomized trials are needed to assess clinical benefits and evaluate newer P2Y12 inhibitors.
Summary: Background: Cardiovascular physiology exhibits circadian rhythms, including a morning surge in platelet reactivity and cardiovascular events. Aligning the timing of antiplatelet therapy with these rhythms may be a simple, cost-effective approach to improve clinical efficacy. This systematic review evaluates the diurnal variability in platelet reactivity among individuals receiving aspirin, clopidogrel, ticagrelor, and prasugrel and explores the potential for timed administration to optimise platelet inhibition and other surrogate cardiovascular markers. Patients and methods: PubMed, Embase, Cochrane Central Register of Controlled Trials, and trial registries (e.g., ClinicalTrials.gov) were searched from 1980 to August 2025 for randomised controlled trials and observational studies in adults investigating morning versus evening dosing or diurnal efficacy. Results: Of 2,340 records, 25 studies were included (17 on aspirin, seven on clopidogrel, one on ticagrelor, and three overlapping with prasugrel). For aspirin, the data showed a tendency that evening administration achieved greater reductions in morning Cyclooxygenase-1 (COX-1)-dependent platelet reactivity in healthy volunteers and cardiovascular disease patients, although there were mixed effects on ambulatory blood pressure. Clopidogrel exhibited diurnal variability, with peaks in Adenosine Diphosphate (ADP)-induced aggregation occurring in the morning, while prasugrel provided more consistent inhibition than clopidogrel or ticagrelor. No studies directly compared evening versus morning dosing for P2Y12-Inhibitors, and clinical outcomes such as major adverse cardiac events were only assessed in one included study. Conclusions: While evening aspirin may enhance chronopharmacological efficacy, the available evidence is limited due to heterogeneity and variable quality. The limited number of studies on agents beyond aspirin highlights a critical research gap, with robust Randomised Controlled Trials needed to evaluate clinical benefits and inform chronotherapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Leinweber et al. (2026) conducted a systematic review in Cardiovascular risk prevention (n=25). Evening versus morning administration of antiplatelet therapy vs. Morning administration was evaluated on Diurnal variability in platelet reactivity. In a systematic review of 25 studies, evening administration of aspirin tended to achieve greater reductions in morning COX-1-dependent platelet reactivity compared to morning dosing.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: